Predicting and Preventing Lung Cancer (Economist)

Summary

An international team identified a 14-protein blood "signature" that predicts lung-cancer risk five or more years before diagnosis, opening the door to drug-based prevention rather than just lifestyle advice. The proteins rise when an inflammatory pathway — driven by interleukin-1 beta (IL-1ß) and triggered by air pollution — activates dormant cancer mutations. Existing IL-1ß-blocking drugs like canakinumab nearly halved lung-cancer risk in the high-signature group, suggesting a targeted preventive therapy validated by a blood test. The work marks a shift toward giving cancer prevention the scientific attention long reserved for treatment.

Key claims

• An 80-scientist team analysed blood from ~50,000 UK Biobank participants with machine learning and found 14 proteins whose levels rise ≥5 years before a lung-cancer diagnosis; results published in Cell on June 4th.
• The 14-protein signature validated across eight other global datasets, including a Taiwanese cohort with few smokers.
• The proteins map to an inflammatory pathway identified in 2023 by Charlie Swanton (Francis Crick Institute): air pollution releases Interleukin-1 Beta (IL-1ß), which activates dormant cancer-causing mutations in lung cells.
• Blocking IL-1ß in pollution-exposed mice stopped tumours forming; in humans, Novartis's 2017 canakinumab heart-attack trial incidentally showed lower lung-cancer rates in the treated group.
• Reanalysed by signature: in low-protein patients >1,500 must be treated to prevent one lung cancer, but in high-protein patients Canakinumab nearly halved risk — just 55 treated to prevent one case (comparable to statins for heart attacks).
• Next steps: a commercial test for the signature, screening other anti-inflammatory drugs; fresh UK Biobank data (next two years) may yield similar clues for other cancers — echoing aspirin's prevention of colorectal cancer in Lynch syndrome patients.

Wikilinks

Cancer Prevention · Lung Cancer · Interleukin-1 Beta (IL-1ß) · Canakinumab · Charlie Swanton · UK Biobank · Protein Biomarkers

The Economist — Science & technology.